ACAD · NASDAQ · STOCK
ACADIA Pharmaceuticals Inc.
$29.41
52W $19.69 – $29.76
69/100
$5.04B
13.1
0.84
Is ACAD Bullish or Bearish?
Bullish.
Innellis AI committee rates ACADIA Pharmaceuticals Inc. (ACAD) Buy with a composite score of 69/100
, based on 6 analysts with 83% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +5.79 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -14.21 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
- EPS growing 96.5% YoY — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
69/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 5%
of 192 Healthcare peers
Value Analyst
bullish
70
/ 100 · High confidence
Classic value case: cheap on multiples with earnings power to back it up
+ P/E of 13.2 is inexpensive for the broad market
Growth Analyst
bullish
85
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 47.0% YoY -- genuine top-line momentum
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 78 is in overbought territory
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 24.3% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 10 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
78.4
Overbought
MACD Histogram
0.303
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.95
Inside Bands
Price vs Moving Averages
EMA 9
$28.13
Above
EMA 21
$26.88
Above
EMA 50
$25.28
Above
EMA 200
$23.54
Above
Fundamental Analysis
Valuation
88
Profitability
100
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
13.1×
P/B Ratio
3.86×
PEG Ratio
0.19
Dividend Yield
0.00%
52W High
$29.76
52W Low
$19.69
Quality & Growth
ROE
3185.6%
ROA
2499.7%
Gross Margin
9113.2%
Operating Margin
758.5%
Revenue Growth YoY
—
Debt / Equity
0.06
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 13.1 (inexpensive relative to a 15-40x range); Price-to-book of 3.9x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 31.9%; Return on assets of 25.0%; Net margin of 33.4%; Gross margin of 91.1%; Current ratio of 3.39 (healthy short-term liquidity); Debt-to-equity of 0.06; Free cash flow per share is positive (1.02); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full ACAD Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →